TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01739088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischemic pre-conditioning stimulus.
Description: Forty eight to 24 hours prior to the surgery, patient assigned to remote ischemic pre-conditioning stimulus (RIPC) will have blood pressure cuffs placed on both lower limbs around the upper thigh, and will then have the cuff inflated around the lower limb to a pressure 10 mmHg above systolic blood pressure for 5 minutes, followed by 5 minutes of cuff deflation. This will be done sequentially on each lower limb for two cycles on each limb. In the operating room, after induction of anesthesia, the exact same procedure will be performed in the RIPC group. For each intervention, the legs will be covered by a drape, so that whether the cuff is being inflated around the leg or underneath the leg is not seen by any member of the health care team.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Ischemic Pre-conditioning
Description: In the control (sham Ischemic Pre-conditioning) group 48 to 24 hours prior to the surgery a cuff will be placed just underneath the upper thigh and the cuff will be inflated for 5 minutes, followed by 5 minutes of cuff deflation, done sequentially for two cycles on each side.In the operating room, after induction of anesthesia, the exact same procedure will be performed in the RIPC group.
Study: NCT02533505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol
Description: Subjects will receive a single dose (2 inhalations) of Symbicort pMDI 160/4.5 μg (2 inhalations; total dosage 320/9.0 μg) or placebo (with a spacer) in a cross-over design (a total of 2 doses of Symbicort and 2 doses of placebo over the duration of the study), and assessments will be made before and after dosing at specified timepoints

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo pMDI 160/4.5 μg
Description: Placebo will be given according at the same dose and schedule as the active comparator - cross-over design.
Study: NCT05924568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational session with Keep Your Move in the Tube and PrimusRS
Study: NCT02499406

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dialectical behavior therapy skills group
Description: Skills training in emotion regulation, distress tolerance, interpersonal effectiveness, and mindfulness
Study: NCT04308109

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Simulation
Description: Simulation involves the use of a highly realistic tracheostomy mannequin and audiovisual devices which will be used to replicate emergent clinical situations. If home invasive ventilation is anticipated, a home ventilator will be used. The simulation will last approximately 2 hours and will end with reviewing the taped session as part of debriefing. Both active arms will occur in the simulation center or sleep lab and replicate the same clinical situations by the same simulation instructor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation
Description: Simulation involves the use of a highly realistic tracheostomy mannequin and audiovisual devices which will be used to replicate emergent clinical situations. If home invasive ventilation is anticipated, a home ventilator will be used. The simulation will last approximately 2 hours and will end with reviewing the taped session as part of debriefing. Both active arms will occur in the simulation center or sleep lab and replicate the same clinical situations by the same simulation instructor.
Study: NCT03789058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: Surgical removal of wisdom teethb with different regimen of Ibuprofen frequency ; three times versus two times .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg
Description: Surgical removal of wisdom teethb with different regimen of Ibuprofen frequency ; three times versus two times .
Study: NCT00059813

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03343262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ta-VNS
Description: The transcutaneous vagus nerve stimulation (taVNS) at auricular concha is a typical representative of TCM modernization. The taVNS regulates the autonomic nervous system, which shows a good therapeutic effect for the treatment of IGT.
Study: NCT01872858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin, 100mg, Q.D, p.o, 2yr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: cilostazol, 100mg, B.I.D, p.o, 2yr
Study: NCT02085005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept AVE0005
Description: Pharmaceutical form:concentrate for infusion Route of administration: intravenous
Study: NCT03343262

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electro-acupuncture
Description: one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Description: one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.
Study: NCT02085005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin SR96669
Description: Pharmaceutical form:solution for infusion Route of administration: intravenous
Study: NCT01255358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone sodium phosphate (2 vials, 250 mg/10 ml each) to be administered via encapsulation into autologous erythrocytes (ERY-DEX system). Final amount administered to the patient: about 10-15 mg of dexamethasone sodium phosphate, encapsulated into autologous blood (2 vials of 250 mg each of dexamethasone sodium phosphate will be used in the ex vivo process together with 50 ml of blood previously taken from the same patient).~The treatment has to be repeated at intervals of 30 days (±10 days)
Study: NCT04011150

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural infusion pump
Description: Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural infusion pump
Description: Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
Study: NCT01787188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam Test Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam Test Capsules
Study: NCT04011150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
Study: NCT01787188

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Study: NCT03585868

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Beverage with no flavonoids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavonoids
Description: Flavonoids-enriched cacao beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: No Flavonoids
Description: Beverage with alkalinized cocoa which eliminates flavonoid content
Study: NCT01398982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine (study group)
Description: At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic saline (control group)
Description: At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline (control group)
Description: At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
Study: NCT04011150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
Study: NCT00530439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Dietician counselling and physical training

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control
Description: Repeated measuring of maternal weight gain, blood samples and ultrasound

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity, dietetic counselling
Description: The active intervention consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.~Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
Study: NCT02792582

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proton Therapy
Description: The protocol-specific radiation dose will be prescribed to a target defined by the use of computerized tomography (CT) and magnetic resonance imaging (MRI). The target will encompass the residual tumor and/or tumor bed and will include a margin mean to treat subclinical microscopic disease. There is no time limit for the interval from surgery or study enrollment to when proton therapy commences. The time course of administration of proton therapy will be 1 treatment/day, 5 days/week, for a period 6 weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proton Therapy
Description: The protocol-specific radiation dose will be prescribed to a target defined by the use of computerized tomography (CT) and magnetic resonance imaging (MRI). The target will encompass the residual tumor and/or tumor bed and will include a margin mean to treat subclinical microscopic disease. There is no time limit for the interval from surgery or study enrollment to when proton therapy commences. The time course of administration of proton therapy will be 1 treatment/day, 5 days/week, for a period 6 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: When possible, tumors will be removed surgically prior to proton therapy. If no tumor remains following surgery, no proton therapy will be given, and participants will be followed for 5 years to collect outcome data for comparison between groups.
Study: NCT06636435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBA-1205
Description: CBA-1205: 0.1, 0.3, 1, 3, 10, 20, 30 mg/kg (Intravenous solution)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBA-1205
Description: CBA-1205 : 20 mg/kg and 30 mg/kg (Intravenous solution)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBA-1205
Description: CBA-1205: 30 mg/kg (Intravenous solution)
Study: NCT01314222

Intervention type: DRUG
Group type: OTHER
Intervention: BMS-954561

Intervention type: DRUG
Group type: OTHER
Intervention: BMS-954561

Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo matching BMS-954561

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo matching BMS-954561

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo matching Pregabalin
Study: NCT04833452

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic dacryocystorhinostomy
Description: Endoscopic DCR

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic dacryocystorhinostomy
Description: Endoscopic DCR
Study: NCT02134769

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bionecteur
Description: Using Bionecteur at each lumina of the catheter; handling according to institutional guideline
Study: NCT01987258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval Walking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous walking
Study: NCT01101581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veltuzumab and 90Y-Epratuzumab Tetraxetan
Description: Veltuzumab will be administered subcutaneously in phase 2. 90Y-Epratuzumab tetraxetan will be administered intravenously. Veltuzumab is given once weekly for 4 weeks. 90Y-Epratuzumab is also given at treatment weeks 2 \& 3 (days 8 \& 15).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-epratuzumab tetraxetan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-epratuzumab tetraxetan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veltuzumab
Description: Veltuzumab will be administered subcutaneously on days 1, 8, 15 and 23
Study: NCT03435822

Intervention type: OTHER
Group type: OTHER
Intervention: asthma action plan management group
Description: Patients will follow the directions in asthma action plan when their asthma get worse.

Intervention type: OTHER
Group type: OTHER
Intervention: conventional management group
Description: Patients will follow the directions in conventional strategy when their asthma get worse.
Study: NCT03016104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magpro X100 + Option
Description: In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ThymatronSystem Ⅳ Electroconvulsive System
Description: In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual (TAU)
Description: Participants will engage in their inpatient treatment program as-usual.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment as usual (TAU)
Description: Participants will engage in their inpatient treatment program as-usual.
Study: NCT04621097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed electromagnetic field
Description: it is a device for magnetotherapy and it is one of the most recent noninvasive physical therapy modality which is used in multiple physical therapy fields . it consist of an appliance, motorized bed and solenoid . the appliance must be connected to electrical supplying 230 =10% at a frequency of 50 or 60 HZ with earth connection . the intensity and spatial lay out of the generated magnetic field depend on the type of solenoid used

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treadmill training
Description: supervised treadmill walking exercise. The exercise program consists of intermittent walking bouts to moderate claudication pain alternating with periods of rest in between for a total of 40-50 minutes .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medication
Description: regular medications
Study: NCT00471185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: 10, 20 and 40 mg of Oral acyline, given on 3 occasions, separated by 1 week.
Study: NCT03291678

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new laparoscopic orchiopexy
Description: closure of the internal ring of the inguinal canal after descending of the testis to scrotum using needle percutaneous

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classic laparoscopic orchiopexy
Description: delivery of abdominal testis into scrotum without closure of the internal ring of the inguinal canal
Study: NCT00420355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir
Description: Atazanavir 300 mg daily on Days 6-12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Description: Lopinavir/ritonavir 400 mg/100 mg twice daily on Days 6-16, then 800 mg/200 mg daily on Days 17-21.
Study: NCT00246441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: 16 weeks treatment; dosing will start at 20 mg/day paroxetine and will increase gradually to a maximum dose of 60 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: treatment phase will last 16 weeks; dosing will start at 20 mg/day (placebo) and will increase gradually to a maximum dose of 60 mg/day.
Study: NCT04659837

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No-Added-Sugar Diet
Description: All participants received a no-added-sugar dietary intervention and followed the diet during the course of the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No-Added-Sugar Diet
Description: All participants received a no-added-sugar dietary intervention and followed the diet during the course of the study.
Study: NCT02962739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine 200 mg/tenofovir alafenamide 25mg
Description: 1 tablet of Descovy contains emtricitabine 200 mg/tenofovir alafenamide 25mg
Study: NCT00293540

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oophorectomy
Description: Excision of an ovary
Study: NCT02962739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine 200 mg/tenofovir alafenamide 25mg
Description: 1 tablet of Descovy contains emtricitabine 200 mg/tenofovir alafenamide 25mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine 200 mg/tenofovir alafenamide 25mg
Description: 1 tablet of Descovy contains emtricitabine 200 mg/tenofovir alafenamide 25mg
Study: NCT00293540

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oophorectomy
Description: Excision of an ovary

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20 mg orally every day
Study: NCT00293540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20 mg orally every day
Study: NCT03516916

Intervention type: OTHER
Intervention: Questionnaires on HRQoL and sociodemography
Description: All patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score.
Study: NCT02256059

Intervention type: PROCEDURE
Intervention: Plate osteosynthesis
Description: Plate osteosynthesis using LCP plate (Synthes)
Study: NCT03516916

Intervention type: OTHER
Intervention: Questionnaires on HRQoL and sociodemography
Description: All patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score.

Intervention type: OTHER
Intervention: Questionnaires on HRQoL and sociodemography
Description: All patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score.
Study: NCT06703346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Letetresgene autoleucel
Description: Drug: Letetresgene autoleucel Letetresgene autoleucel will be administered. Drug: Cyclophosphamide Cyclophosphamide will be used as a lymphodepleting chemotherapy. Drug: Fludarabine Fludarabine will be used as a lymphodepleting chemotherapy.
Study: NCT00874757

Intervention type: DRUG
Intervention: Rosuvastatin
Description: Healthy subjects received rosuvastatin 20 mg orally for 3 weeks. Inflammatory markers measured pre- and post- rosuvastatin treatment.
Study: NCT03143205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARENESS for Sexual Minorities
Description: 9 session, individually delivered, cognitive behavioral intervention focused on modifying sexual minority stress responses to reduce the impact of sexual minority stress experiences.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Writing tasks
Description: Writing sessions to explore daily activities.